| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $3.5M | — | +20.7% |
| R&D Expense | $1.1M | — | +169.0% |
| SG&A Expense | $10.3M | — | +91.2% |
| Operating Income | -$8.1M | — | -119.6% |
| Net Income | -$6.5M | — | -222.8% |
| EPS (Basic) | -$0.30 | — | -130.8% |
| EPS (Diluted) | -$0.32 | — | -146.2% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $54.2M | -17.9% | +19.2% |
| Accounts Receivable | $3.6M | -15.5% | +746.3% |
| Inventory | $6.0M | +18.0% | +584.2% |
| Current Assets | $68.6M | -13.2% | +42.5% |
| Total Assets | $69.2M | -13.1% | +42.5% |
| Current Liabilities | $5.4M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$11.8M | — | -477.1% |
| Capital Expenditures | $1K | — | -97.9% |
| Investing Cash Flow | -$1K | — | +97.9% |
| Financing Cash Flow | $800 | — | +100.1% |
| Free Cash Flow | -$11.8M | — | -459.9% |
| +93.2% |
| Total Liabilities | $11.8M | -31.4% | +51.2% |
| Stockholders' Equity | $57.5M | -8.1% | +40.8% |